{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:53:34Z","timestamp":1793681614721,"version":"4.5.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Targeted therapies and immune-based treatments have transformed the management of hematologic malignancies. However, these agents can also result in unintended ocular adverse effects. These toxicities are often underrecognized but may significantly affect patient quality of life and therapeutic decision-making. A comprehensive understanding of these effects is essential for interdisciplinary management. This review synthesizes the current evidence regarding ocular toxicities associated with modern targeted and immune therapies used in hematologic cancers. Data were drawn from case reports, clinical trials, observational studies, and pharmacovigilance databases. Ocular side effects were reported across all major therapy classes, including cell therapies, kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, antibody\u2013drug conjugates, and proteasome inhibitors. Chimeric antigen receptor T-cell therapies commonly induce neuro-ophthalmic symptoms such as photophobia and visual disturbances, frequently in association with neurotoxicity syndromes. Tyrosine kinase inhibitors were associated with a range of effects, including periorbital edema, uveitis, and retinal vascular complications. Immune checkpoint inhibitors caused inflammatory eye diseases such as uveitis, optic neuritis, and ocular myasthenia, consistent with immune-related adverse events. Certain antibody\u2013drug conjugates, particularly those used in multiple myeloma, produced high rates of ocular surface disease that required dose modifications. While many adverse effects were reversible, some caused vision-threatening complications that required prompt ophthalmologic intervention. Pediatric-specific data were sparse, and long-term ocular outcomes remain poorly defined. Ocular toxicities from modern hematologic cancer therapies span a broad clinical spectrum and vary by drug class. Increased awareness of these complications among oncologists and ophthalmologists can support earlier detection and treatment. Accurate clinical descriptions of ocular adverse events and effective management recommendations in these settings will help improve patient outcomes and their quality of life.<\/jats:p>","DOI":"10.3389\/fonc.2025.1691518","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:40:32Z","timestamp":1767681632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies"],"prefix":"10.3389","volume":"15","author":[{"given":"Mohammad S.","family":"Aqil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yzen","family":"Al-Marrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Yaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abu-Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Gopishetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Idogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ezekwudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishmael","family":"Jaiyesimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR-T cell therapy for hematological Malignancies: Limitations and optimization strategies","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer","volume":"15","author":"Simao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.36401\/JIPO-20-21","article-title":"Targeted cancer therapy and its ophthalmic side effects: A review","volume":"4","author":"Bindiganavile","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/ejh.14208","article-title":"Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review","volume":"113","author":"Frey","year":"2024","journal-title":"Eur J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1188\/16.Onf.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis","year":"2016","journal-title":"Oncol Nurs Forum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-320814","article-title":"Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review","volume":"107","author":"Mumtaz","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","unstructured":"Tecvayli (teclistamab-cqyv) injection, for subcutaneous use\n          \n          \n          \n          2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflammation Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul Immunol Inflammation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2018.07.008","article-title":"Optic neuropathy in extramedullary, blast crisis of chronic myeloid leukemia","volume":"54","author":"Elizondo Leal","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.769315","article-title":"Safety profile of ibrutinib: an analysis of the WHO pharmacovigilance database","volume":"12","author":"Allouchery","year":"2021","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101300","article-title":"Ibrutinib-related uveitis: A case series","volume":"25","author":"Chiu","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S518","DOI":"10.1016\/S2152-2650(24)01605-7","article-title":"MCL-640 ibrutinib-induced uveitis: A case of rapid ocular toxicity in mantle cell lymphoma","volume":"24","author":"Ramachandran","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10792-021-02058-8","article-title":"Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review","volume":"42","author":"Dammacco","year":"2022","journal-title":"Int Ophthalmol"},{"key":"B20","unstructured":"Rydapt (midostaurin) capsules, for oral use\n          \n          \n          \n          2017"},{"key":"B21","unstructured":"XOSPATA (gilteritinib) tablets, for oral use\n          \n          \n          \n          2022"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13643-021-01782-7","article-title":"Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature","volume":"10","author":"Mu\u00f1oz-Ortiz","year":"2021","journal-title":"Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-249735","article-title":"Choroidal effusion: a rare and unusual complication of daratumumab","volume":"15","author":"Singh","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12886-019-1118-x","article-title":"Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series","volume":"19","author":"Sklar","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","article-title":"Association between bortezomib therapy and eyelid chalazia","volume":"134","author":"Fraunfelder","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14733","article-title":"Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br J Haematol"},{"key":"B28","unstructured":"Ninlaro (ixazomib) capsules, for oral use\n          \n          \n          \n          2022"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0220","article-title":"Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database","volume":"16","author":"Zhao","year":"2024","journal-title":"Immunotherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17634","article-title":"Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101933","article-title":"Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia","volume":"32","author":"Moon","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B39","unstructured":"XALKORI (crizotinib) capsules and oral pellets\n          \n          \n          \n          2023"},{"key":"B40","unstructured":"VENCLEXTA (venetoclax tablets), for oral use\n          \n          \n          \n          2024"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"key":"B42","unstructured":"Report on the deliberation results\n          \n          \n          \n          2018"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011049","article-title":"Venclexta: Side effects and how to manage them","author":"Lewis","year":"2022","journal-title":"Healthgrades"},{"key":"B44","unstructured":"BALVERSA (erdafitinib) tablets, for oral use\n          \n          \n          \n          2024"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004556","article-title":"Erdafitinib-induced bilateral multifocal serous retinal detachments and severe dry eye related unilateral peripheral ulcerative keratitis in a patient with metastatic urothelial carcinoma","volume":"11","author":"Kayabasi","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"B48","unstructured":"Iclusig (ponatinib) tablets, for oral use\n          \n          \n          \n          2020"},{"key":"B49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12348-025-00484-8","article-title":"Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review","volume":"15","author":"Zhang","year":"2025","journal-title":"J Ophthalmic Inflammation Infect"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","volume":"44","author":"Arai","year":"2017","journal-title":"J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci42440","article-title":"A look at autoimmunity and inflammation in the eye","volume":"120","author":"Caspi","year":"2010","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.12.013","article-title":"Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment","volume":"224","author":"Braun","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030336","article-title":"Diagnosing and managing uveitis associated with immune checkpoint inhibitors: A review","volume":"14","author":"Zhang","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American academy of ophthalmology intelligent research in sight registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune checkpoint inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","article-title":"Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological Malignancies: A French nationwide study","volume":"67","author":"Bayer","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12883-018-1222-1","article-title":"Rebound of relapses after discontinuation of rituximab in a patient with MOG-IgG1 positive highly relapsing optic neuritis: a case report","volume":"18","author":"Choi","year":"2018","journal-title":"BMC Neurol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.4.4","article-title":"Management of ocular toxicity in patients receiving belantamab mafodotin","volume":"14","author":"Lu","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"B61","volume-title":"Blenrep: EPAR \u2013 Public assessment report","year":"2025"},{"key":"B62","volume-title":"GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed\/refractory multiple myeloma","year":"2025"},{"key":"B63","volume-title":"Gemtuzumab Ozogamicin","year":"2012"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1691518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:40:37Z","timestamp":1767681637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1691518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":63,"alternative-id":["10.3389\/fonc.2025.1691518"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1691518","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1691518"}}